Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates - Archive ouverte HAL Access content directly
Journal Articles Vaccine Year : 2020

Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates

(1) , (1) , (1) , (1) , (1) , (1) , (1) , (2) , (3) , (4) , (5) , (4) , (2) , (5) , (3) , (1) , (1) , (1) , (1) , (1) , (6)
1
2
3
4
5
6
Alessia Biolchi
  • Function : Author
  • PersonId : 1102519
Gabriella de Angelis
  • Function : Author
  • PersonId : 1102520
Monica Moschioni
  • Function : Author
  • PersonId : 1102521
Sara Tomei
  • Function : Author
  • PersonId : 1102522
Brunella Brunelli
  • Function : Author
  • PersonId : 1102523
Maria Giuliani
  • Function : Author
  • PersonId : 1102524
Stefania Bambini
  • Function : Author
  • PersonId : 1102525
Ray Borrow
  • Function : Author
  • PersonId : 1043395
Heike Claus
  • Function : Author
  • PersonId : 1102526
Jay Lucidarme
  • Function : Author
  • PersonId : 1102527
Ulrich Vogel
  • Function : Author
  • PersonId : 987943
Sonia Budroni
  • Function : Author
  • PersonId : 1102528
Marzia M Giuliani
  • Function : Author
  • PersonId : 1102529
Rino Rappuoli
  • Function : Author
  • PersonId : 1102530
Mariagrazia Pizza
  • Function : Author
  • PersonId : 1102531

Abstract

Background: The multicomponent meningococcal serogroup B vaccine (4CMenB) is currently indicated for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB). However, genes encoding the 4CMenB antigens are also variably present and expressed in strains belonging to other meningococcal serogroups. In this study, we evaluated the ability of antibodies raised by 4CMenB immunisation to induce complement-mediated bactericidal killing of non-MenB strains. Methods: A total of 227 invasive non-MenB disease isolates were collected between 1 July 2007 and 30 June 2008 from England and Wales, France, and Germany; 41 isolates were collected during 2012 from Brazil. The isolates were subjected to genotypic analyses. A subset of 147 isolates (MenC, MenW and MenY) representative of the meningococcal genetic diversity of the total sample were tested in the human complement serum bactericidal antibody assay (hSBA) using sera from infants immunised with 4CMenB. Results: Serogroup and clonal complex repertoires of non-MenB isolates were different for each country. For the European panel, MenC, MenW and MenY isolates belonged mainly to ST-11, ST-22 and ST-23 complexes, respectively. For the Brazilian panel, most MenC and MenW isolates belonged to the ST-103 and ST-11 complexes, respectively, and most MenY isolates were not assigned to clonal complexes. Of the 147 non-MenB isolates, 109 were killed in hSBA, resulting in an overall coverage of 74%. Conclusion: This is the first study in which 147 non-MenB serogroup isolates have been analysed in hSBA to evaluate the potential of a MenB vaccine to cover strains belonging to other serogroups. These data demonstrate that antibodies raised by 4CMenB are able to induce bactericidal killing of 109 non-MenB isolates, representative of non-MenB genetic and geographic diversity. These findings support previous evidence that 4CMenB immunisation can provide cross-protection against non-MenB strains in infants, which represents an added benefit of 4CMenB vaccination.
Fichier principal
Vignette du fichier
pmid33036804.pdf (1023.59 Ko) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

pasteur-03265134 , version 1 (18-06-2021)

Licence

Attribution - CC BY 4.0

Identifiers

Cite

Alessia Biolchi, Gabriella de Angelis, Monica Moschioni, Sara Tomei, Brunella Brunelli, et al.. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. Vaccine, 2020, 38 (47), pp.7542 - 7550. ⟨10.1016/j.vaccine.2020.09.050⟩. ⟨pasteur-03265134⟩

Collections

PASTEUR
4 View
30 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More